Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
Myeloproliferative neoplasms (MPNs) are a group of rare conditions where the bone marrow makes too many blood cells. Standard treatments aim to lower these counts, but they do not always work well enough for everyone. When this happens, long-term inflammation in the body can drive troublesome symptoms like itchy skin, fever, and night sweats. This early-stage clinical trial tests a drug named Kineret (anakinra). Kineret is already used for other inflammatory conditions and works by blocking a specific protein that causes swelling and irritation. Researchers want to find out if taking Kineret as an injection under the skin helps reduce inflammation in MPN patients. Over six months, doctors will check if Kineret improves blood counts, shrinks inflammation markers, and helps people feel better in their everyday lives.
At a glance
What is this study about?
Inside our bones, spongy bone marrow acts like a factory producing red blood cells, white blood cells, and platelets. In people with myeloproliferative neoplasms (MPNs), this factory produces far too many blood cells. Over time, this overproduction can cause tiredness, enlarged organs, and raised risks of blood clots. While medicines exist to slow the factory down, some people find their condition resists these standard treatments.
Doctors have noticed that high levels of inflammation often accompany MPNs. This ongoing internal inflammation can make patients feel unwell, causing persistent fevers, heavy night sweats, and severe itching. Scientists believe that targeting inflammation directly might help bring the blood condition under better control. This trial investigates a medicine called Kineret (anakinra), which works by blocking interleukin-1, a key chemical messenger that triggers inflammation.
By adding Kineret to care plans, researchers hope to see whether turning down the body's inflammatory response can improve blood cell numbers and ease day-to-day symptoms. The results will help doctors understand whether anti-inflammatory drugs have a future role in treating MPNs when standard medicines are no longer doing the job.
Key takeaways
- Tests Kineret injections for people with MPNs that resist standard treatment.
- Aims to reduce body-wide inflammation and relieve symptoms like itching and night sweats.
- Open to adults aged 18 and over.
- Involves daily self-injections and clinic visits over a six-month period.
- Requires blood tests, symptom scores, and keeping a daily treatment diary.
Who may be eligible?
This trial is open to adults aged 18 and older who have been diagnosed with a myeloproliferative neoplasm. To be considered, your condition must be resistant to standard cell-reducing treatments, meaning your current therapy is not managing your blood counts or symptoms well enough.
Men and women of all backgrounds may join. However, because Kineret affects the immune system, people with active, serious infections or certain other significant health conditions may not be able to participate safely.
Your hospital haematology team will carry out detailed health checks, including blood tests, to make sure this trial is medically suitable and safe for you before you can take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with a myeloproliferative neoplasm (MPN).
- My current treatment is not controlling my blood counts or symptoms well enough.
- I am willing and able to give myself daily injections under the skin.
- I can attend hospital visits at the start, at 3 months, and at 6 months.
What does participation involve?
If you join the trial, you will take Kineret as an injection just under the skin using a pre-filled syringe. You will be taught how to do these injections yourself at home, and you will keep a daily diary to record each dose over the first three months.
The study lasts around six months in total. You will have clinic visits at the start (baseline), at three months, and at six months. During these visits, doctors will take blood samples to measure your blood counts, track inflammation levels, and check genetic markers linked to MPNs.
You will also be asked to fill in simple questionnaires about your quality of life and rate specific symptoms—such as itching, fevers, and night sweats—using a 1 to 10 scale. The trial team will monitor your safety closely throughout the entire period.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is Kineret?
Kineret (anakinra) is an established medicine that blocks an inflammatory protein in the body called interleukin-1. It is already used to treat other inflammatory conditions like rheumatoid arthritis.
How do I take the medicine?
It is given as an injection under the skin using a ready-to-use syringe. A nurse will show you how to safely give yourself these injections at home.
Will I have to stop my current MPN medicines?
This depends on the exact trial protocol. Your study doctor will explain whether Kineret is added to your existing routine or replaces a part of it.
How long will I be in the study?
The study monitors your health closely for about six months, with key check-ups at the start, at three months, and at six months.
What happens if I change my mind?
Joining is completely voluntary. You can stop participating at any point, and your usual medical team will continue to look after you just as before.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.